AMMAX BIO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2020-03-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ammaxbio.com
Clinical Trials
16
Active:7
Completed:5
Trial Phases
2 Phases
Phase 1:9
Phase 2:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (56.3%)Phase 2
7 (43.8%)A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
Phase 2
Withdrawn
- Conditions
- IPF
- Interventions
- Biological: AMB-05XDrug: Placebo
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- AmMax Bio, Inc.
- Registration Number
- NCT05349760
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
Phase 2
Completed
- Conditions
- Pigmented Villonodular SynovitisTGCTTenosynovial Giant Cell Tumor
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- AmMax Bio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05349643
- Locations
- 🇳🇱
AmMax Bio, Clinical Site, Leiden, Netherlands
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
Phase 2
Terminated
- Conditions
- TGCTTenosynovial Giant Cell TumorPigmented Villonodular SynovitisPVNS - Pigmented Villonodular Synovitis
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- AmMax Bio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT04938180
- Locations
- 🇺🇦
AmMax Bio Clinical Site, Kyiv, Ukraine
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
Phase 2
Completed
- Conditions
- Tenosynovial Giant Cell TumorPigmented Villonodular Synovitis (PVNS)
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- AmMax Bio, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04731675
- Locations
- 🇺🇦
AmMax Bio Clinical Site, Kyiv, Ukraine
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
Phase 1
Completed
- Conditions
- Pancreatic CancerColorectal CancerNon-Small Cell Lung Cancer
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- AmMax Bio, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT02713529
- Locations
- 🇪🇸
Research Site, Madrid, Spain
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Prev
- 1
- 2
- Next
News
No news found